NASDAQ:CNAT

Conatus Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.96
0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.95
▼
$0.98
50-Day Range
$0.56
▼
$1.34
52-Week Range
$0.23
▼
$1.07
Volume1.37 million shs
Average Volume1.28 million shs
Market Capitalization$31.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Conatus Pharmaceuticals logo

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Headlines

Conatus Pharmaceuticals Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population
Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population
September 6, 2020 |  bloomberg.com
CNAT Jan 2021 2.500 call
CNAT Jan 2021 2.500 call
August 22, 2020 |  ca.finance.yahoo.com
CNAT Oct 2020 2.500 call
CNAT Oct 2020 2.500 call
August 20, 2020 |  ca.finance.yahoo.com
News for Conatus Pharmaceuticals Inc
News for Conatus Pharmaceuticals Inc
August 1, 2020 |  markets.businessinsider.com
Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
July 23, 2020 |  www.bloomberg.com
Histogen completes tie-up with Conatus Pharma
Histogen completes tie-up with Conatus Pharma
May 27, 2020 |  seekingalpha.com
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
May 18, 2020 |  finance.yahoo.com
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
May 14, 2020 |  finance.yahoo.com
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
May 11, 2020 |  finance.yahoo.com
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
May 7, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.66 out of 5 stars

Medical Sector

1357th out of 2,096 stocks

Pharmaceutical Preparations Industry

611th out of 830 stocks

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

What stocks does MarketBeat like better than Conatus Pharmaceuticals?

Wall Street analysts have given Conatus Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Conatus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.
View Conatus Pharmaceuticals' earnings history.

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the following people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications

Who are some of Conatus Pharmaceuticals' key competitors?

Some companies that are related to Conatus Pharmaceuticals include BioLineRx (BLRX), Eledon Pharmaceuticals (ELDN), Vascular Biogenics (VBLT), Minerva Neurosciences (NERV), Aileron Therapeutics (ALRN), Graybug Vision (GRAY), Cocrystal Pharma (COCP), Gain Therapeutics (GANX), ASLAN Pharmaceuticals (ASLN), LifeVantage (LFVN), Sio Gene Therapies (SIOX), Lipocine (LPCN), Lotus Pharmaceuticals (LTUS), Acasti Pharma (ACST) and Aptevo Therapeutics (APVO).
View all of CNAT's competitors.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $0.96.

How much money does Conatus Pharmaceuticals make?

Conatus Pharmaceuticals has a market capitalization of $31.94 million and generates $21.72 million in revenue each year.

How many employees does Conatus Pharmaceuticals have?

Conatus Pharmaceuticals employs 30 workers across the globe.

What is Conatus Pharmaceuticals' official website?

The official website for Conatus Pharmaceuticals is www.conatuspharma.com.

Where are Conatus Pharmaceuticals' headquarters?

Conatus Pharmaceuticals is headquartered at 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.